NYSE:LLYPharmaceuticals
Eli Lilly Weight Loss Push Weighs On Valuation And Growth Hopes
FDA decision pending on Eli Lilly’s oral weight loss drug orforglipron, a key regulatory milestone for NYSE:LLY.
Company planning a US$3b investment in China to manufacture orforglipron locally and work with regional partners.
Moves aimed at scaling Eli Lilly’s global obesity franchise and expanding manufacturing capacity for weight management treatments.
Eli Lilly, traded as NYSE:LLY, is pushing further into obesity care with orforglipron, an oral therapy under review by the FDA. For...